Results 31 to 40 of about 14,957,077 (381)

Impact of Manufacturing Procedures on CAR T Cell Functionality

Frontiers in Immunology, 2022
The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in the past few decades. As of today, there are six CAR T cell products that have been approved by the FDA: KYMRIAH (tisagenlecleucel, CD19 CAR T cells), YESCARTA ...
Norihiro Watanabe, Feiyan Mo, Feiyan Mo, Mary Kathryn McKenna   +3 more
doaj   +1 more source

Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

New England Journal of Medicine, 2019
BACKGROUND Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T‐cell therapy that targets B‐cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS In this phase 1 study involving patients with
N. Raje, J. Berdeja, Yi Lin, D. Siegel, S. Jagannath, D. Madduri, M. Liedtke, J. Rosenblatt, M. Maus, Ashley Turka, L. Lam, R. Morgan, Kevin G. Friedman, M. Massaro, Julie Wang, G. Russotti, Zhihong Yang, T. Campbell, K. Hege, F. Petrocca, Travis Quigley, N. Munshi, J. Kochenderfer   +22 more
semanticscholar   +1 more source

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]

, 2019
BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena, Eggert, Angelika, Flemmig, Carina, Grunewald, Laura, Henssen, Anton, Jensen, Michael C., Joussen, Antonia, Klaus, Anika, Künkele, Annette, Radke, Josefine, Rossig, Claudia, Schulte, Johannes H., Schumann, Elisa, Schwiebert, Silke, Winkler, Annika, Zirngibl, Felix   +15 more
core   +2 more sources

Pharmacologic Control of CAR T Cells [PDF]

International Journal of Molecular Sciences, 2021
Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors.
Benjamin Caulier, Jorrit M. Enserink, Sébastien Wälchli   +2 more
openaire   +4 more sources

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia [PDF]

, 2016
Background Elderly patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have poor prognosis. Autologous CD19 chimeric antigen receptor-modified T (CAR-T) cells have potentials to cure patients with B cell ALL; however, safety and ...
Bingxia Li, Bo Cai, Bo Yao, Changlin Yu, Hanren Dai, Hongli Zuo, Huisheng Ai, Jianhui Qiao, Jun Yang, Kaixun Hu, Mei Guo, Mingxing Feng, Qiyun Sun, Tieqiang Liu, Weidong Han, Yajing Huang, Yajing Zhang, Yao Wang, Yelei Guo, Yi Wang, Yujing Sun, Zechuan Zhang, Zheng Dong, Zhiqing Liu   +23 more
core   +5 more sources

Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway

Oncogenesis, 2021
Pancreatic carcinoma (PC) is one of the most common malignancies. Chimeric antigen receptor (CAR)-modified T cells has achieved remarkable efficacy in the treatment of hematological malignancies.
Yaoxin Gao, Haizhen Lin, Dandan Guo, Sijia Cheng, Ying Zhou, Li Zhang, Jie Yao, Muhammad Asad Farooq, Iqra Ajmal, Yixin Duan, Cong He, Lei Tao, Shijia Wu, Mingyao Liu, Wenzheng Jiang   +14 more
doaj   +1 more source

Glycan-directed CAR-T cells [PDF]

Glycobiology, 2018
Cancer immunotherapy is rapidly advancing in the treatment of a variety of hematopoietic cancers, including pediatric acute lymphoblastic leukemia and diffuse large B cell lymphoma, with chimeric antigen receptor (CAR)-T cells. CARs are genetically encoded artificial T cell receptors that combine the antigen specificity of an antibody with the ...
Steentoft, Catharina, Migliorini, Denis, King, Tiffany R, Mandel, Ulla, June, Carl H, Posey, Avery D   +5 more
openaire   +3 more sources

TGF-β-responsive CAR-T cells promote anti-tumor immune function. [PDF]

, 2018
A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-β) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant.
Chang, ZeNan L, Chen, Yvonne Y, Hou, Andrew J, Lorenzini, Michael H, Zah, Eugenia   +4 more
core   +1 more source

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

Journal of Hematology & Oncology, 2019
The current treatment for pediatric acute lymphoblastic leukemia (ALL) is highly successful with high cure rate. However, the treatment of adult ALL remains a challenge, particularly for refractory and/or relapsed (R/R) ALL.
Juanjuan Zhao, Yongping Song, Delong Liu
doaj   +1 more source

IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors

Frontiers in Oncology, 2021
Chimeric antigen receptor T (CAR-T) cells are not effective in solid tumor treatment due to reduced invasion and expansion, and short survival time. This study aimed to explore whether interleukin (IL)-7 and CCR2b expression could improve GD2-CAR-T cell ...
Guangchao Li, Guangchao Li, Qing Zhang, Zeping Han, Yangmin Zhu, Huijuan Shen, Zhi Liu, Zhao Zhou, Wen Ding, Siqi Han, Jinhua He, Zhao Yin, Jie Zhou, Ruiming Ou, Min Luo, Min Luo, Shuang Liu   +16 more
doaj   +1 more source